Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Microscopically positive resection margin after hepatoblastoma resection: what is the impact on prognosis? A Childhood Liver Tumours Strategy Group (SIOPEL) report.
Aronson DC, Weeda VB, Maibach R, Czauderna P, Dall'Igna P, de Ville de Goyet J, Branchereau S, Perilongo G, Brock P, Zsiros J, Semeraro M, Chardot C, Wildhaber B, Morland B, Brugières L; Childhood Liver Tumour Strategy Group (SIOPEL). Aronson DC, et al. Among authors: morland b. Eur J Cancer. 2019 Jan;106:126-132. doi: 10.1016/j.ejca.2018.10.013. Epub 2018 Dec 5. Eur J Cancer. 2019. PMID: 30528797
A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Société Française d'Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG).
Vassal G, Giammarile F, Brooks M, Geoerger B, Couanet D, Michon J, Stockdale E, Schell M, Geoffray A, Gentet JC, Pichon F, Rubie H, Cisar L, Assadourian S, Morland B. Vassal G, et al. Among authors: morland b. Eur J Cancer. 2008 Nov;44(16):2453-60. doi: 10.1016/j.ejca.2008.08.003. Epub 2008 Sep 21. Eur J Cancer. 2008. PMID: 18812255 Clinical Trial.
Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma.
Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Perilongo G, et al. Among authors: morland b. N Engl J Med. 2009 Oct 22;361(17):1662-70. doi: 10.1056/NEJMoa0810613. N Engl J Med. 2009. PMID: 19846851 Free article. Clinical Trial.
Prognostic stratification for children with hepatoblastoma: the SIOPEL experience.
Maibach R, Roebuck D, Brugieres L, Capra M, Brock P, Dall'Igna P, Otte JB, De Camargo B, Zsiros J, Zimmermann A, Aronson D, Childs M, Scopinaro M, Morland B, Plaschkes J, Czauderna P, Perilongo G. Maibach R, et al. Among authors: morland b. Eur J Cancer. 2012 Jul;48(10):1543-9. doi: 10.1016/j.ejca.2011.12.011. Epub 2012 Jan 13. Eur J Cancer. 2012. PMID: 22244829 Clinical Trial.
Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma--a phase II trial of the childhood liver tumour strategy group (SIOPEL).
Zsíros J, Brugières L, Brock P, Roebuck D, Maibach R, Child M, Morland B, Casanova M, Pariente D, Paris C, de Camargo B, Ronghe M, Zimmermann A, Plaschkes J, Czauderna P, Perilongo G. Zsíros J, et al. Among authors: morland b. Eur J Cancer. 2012 Dec;48(18):3456-64. doi: 10.1016/j.ejca.2012.06.023. Epub 2012 Jul 24. Eur J Cancer. 2012. PMID: 22835780 Clinical Trial.
Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study.
Zsiros J, Brugieres L, Brock P, Roebuck D, Maibach R, Zimmermann A, Childs M, Pariente D, Laithier V, Otte JB, Branchereau S, Aronson D, Rangaswami A, Ronghe M, Casanova M, Sullivan M, Morland B, Czauderna P, Perilongo G; International Childhood Liver Tumours Strategy Group (SIOPEL). Zsiros J, et al. Among authors: morland b. Lancet Oncol. 2013 Aug;14(9):834-42. doi: 10.1016/S1470-2045(13)70272-9. Epub 2013 Jul 4. Lancet Oncol. 2013. PMID: 23831416 Free PMC article.
178 results